Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients.

Zhibo Tan,Xiaohan Zhang,Pingju Zheng,Weixi Shen,Chao Yang

doi:10.18632/oncotarget.17604

Zhibo Tan, Xiaohan Zhang + Show 3 more

Open Access

https://doi.org/10.18632/oncotarget.17604

Copy DOI

Journal: Oncotarget	Publication Date: May 4, 2017
Citations: 30	License type: cc-by

Affiliation: Southern Medical University Shenzhen Hospital

Abstract

Glucose transporter 1 (GLUT1) plays an important role in the transport and metabolism of glucose in cancer cells. An increasing number of studies have explored the connection between GLUT1 expression and prognosis in non-small cell lung cancer (NSCLC), but the results have been controversial. Therefore, we conducted a meta-analysis to obtain a comprehensive evaluation of the prognostic value of GLUT1 in NSCLC. Relevant studies from PubMed, Embase, and Web of Science were searched. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the effective measures. A total of 10 studies involving 1,665 patients were included in this meta-analysis. The results showed that GLUT1 overexpression was associated with poor overall survival (HR = 2.21; 95% CI, 1.42–3.42; p < 0.001) and disease-free survival (HR = 1.73; 95% CI, 1.35–2.23; p < 0.001). Furthermore, elevated GLUT1 expression correlated with sex (OR = 2.29; 95% CI, 1.17–4.49; p = 0.015), advanced tumor stage (OR = 2.46; 95% CI, 1.79–3.38; p < 0.001), histology (OR = 6.99; 95% CI, 4.71–10.38; p < 0.001), and large tumor size (OR = 2.77; 95% CI, 1.73–4.44; p < 0.001). This meta-analysis revealed overexpression of GLUT1 to be a biomarker of worse prognosis in NSCLC.

Highlights

Lung cancer is a lethal cancer with the highest incidence among all cancer types worldwide [1]
A number of studies have explored the prognostic significance of Glucose transporter 1 (GLUT1) in Nonsmall cell lung cancer (NSCLC); results have been inconsistent, which prompted this meta-analysis to obtain an objective view of this issue
The results demonstrated that GLUT1 was an indicator for worse overall survival (OS) and disease-free survival (DFS)

Summary

Introduction

Lung cancer is a lethal cancer with the highest incidence among all cancer types worldwide [1]. Nonsmall cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [2]. Great progresses have been made in terms of treatment strategies for NSCLC [3, 4]; long-term survival remains unsatisfactory with a 5-year survival rate as low as 16.3%[2, 5]. The fact that prognostic parameters are lacking is one important reason for the disappointing prognosis [5]. Several clinical features, including pathological stage, gene mutational status [4], and smoking history have been used as biomarkers for prognostication. They only provide crude measures of the aggressiveness of NSCLC.

Methods

Results

Conclusion